A Novel Anti-Polysaccharide Antiserum for Detection of Clostridium Difficile Bacteria, and Diagnosis of Clostridium Difficile Colonization in Complex Clinical Specimens

Technology #ua17-056

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Gayatri Vedantam
Associate professor, Animal and Comparative Biomedical Sciences
Virinchipuram Viswanathan
Associate Professor, SACBC
Managed By
Tod McCauley
Sr. Licensing Manager (520) 626-7916

Title: A Novel Anti-Polysaccharide Antiserum for Detection of Clostridium difficile Bacteria, and Diagnosis of Clostridium difficile Colonization in Complex Clinical Specimens

 

Invention: The technology is an antiserum that is highly specific for Clostridium difficile. This target is available on all clinically relevant strains of Clostridium difficile bacteria.

 

Background: Clostridium difficile is a bacteria that causes serious intestinal issues. Each year there are approximately 500,000 cases of Clostridium difficile in the United States, which results in $4 billion in healthcare costs. The key to treating this infection and preventing recurrent infections is early, accurate diagnosis. Unfortunately, individuals with a low quantity of Clostridium difficile or non-toxic strains cannot be identified.

 

Applications:

  • Diagnostic assays
  • Health-systems
  • Laboratories

 

Advantages:

  • Reduces repeat testing
  • Highly specific to Clostridium difficile only

 

Licensing Manager:

Tod McCauley

TodM@tla.arizona.edu

(520) 626-7916